A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.
The combination of drugs – which both work by blocking signals cancer … Read more
By Ian Ingram
For women with recurrent or persistent low-grade serous ovarian cancer (LGSOC), presence of a KRAS mutation appeared to predict benefit from binimetinib (Mektovi), a post-hoc analysis from the phase III MILO trial found.
Among women treated with … Read more
By Denise Myshko
Trametinib (Mekinist) monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study, according to David M. … Read more
By Pam Harrison
Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer.
Trametinib (Mekinist) treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care … Read more
